stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

BeOne Medicines AG

Switzerland · NASDAQ: ONC · Market cap: · P/E: · P/S:

BeOne Medicines develops and sells cancer drugs for patients around the world.

BeOne Medicines is a cancer drug company. It discovers, develops, and sells medicines that treat tumors, and it sells them in markets around the world, from the United States and Europe to Asia and beyond.

BeOne Medicines AG (ONC) Brukinsa: line art illustration of A Brukinsa capsule-style medicine bottle with its label
Brukinsa
Brukinsa is a pill used to treat certain lymphomas and leukemias.

Its best-known product is Brukinsa, a pill for certain blood cancers such as chronic lymphocytic leukemia. Brukinsa is the company's profit engine and the main reason it has grown into a global player. The company also sells tislelizumab, an immune-boosting cancer drug, and a portfolio of other cancer therapies. Customers are doctors, hospitals, and health systems, and the payers are insurers and government health programs, which is why winning regulatory approval and reimbursement in each country matters so much. The company was long known as BeiGene, a name built on selling lower-cost cancer drugs and running huge clinical trials in China. It rebranded to BeOne Medicines and moved its legal home to Switzerland, cementing its identity as a global oncology company rather than a China-focused one. The business has burned cash for years while building its pipeline, and it has been pushing toward profitability as Brukinsa sales scale up worldwide. Competition is fierce — it sells into the same blood-cancer market as AbbVie and Johnson & Johnson, among others.


The core bet is simple: keep launching and expanding cancer drugs, get them approved and paid for in more countries, and let the global sales base carry the cost of research. The company spends heavily on trials and manufacturing to make that happen. Its future hinges on whether Brukinsa keeps growing and whether newer drugs in its pipeline can turn into the next big sellers.

Saved answer · last researched 16 Nov 2026